You have been taking Wegovy, Ozempic or Mounjaro for several months. The weight was coming off steadily — and then it stopped. The scale barely moves, even though you are still injecting every week and you have not changed your eating habits. You wonder: has the medication stopped working? Am I doing something wrong?

The answer, in most cases, is no. A weight-loss plateau is one of the most predictable phases of GLP-1 treatment. Understanding why it happens — and what you can actually do about it — makes all the difference.

What exactly is a weight-loss plateau?

A weight-loss plateau is generally defined as a period of four or more weeks during which your weight remains stable despite continuing medication and not consciously eating more. It is not a temporary fluctuation caused by water retention or a heavy meal — it is a sustained pause in the downward trend.

This is different from the medication simply not working at all. During a plateau, the medication is still suppressing appetite and slowing gastric emptying, but the net effect on the scale has flattened out. The two main reasons for this are metabolic adaptation and the body reaching a new set-point.

Why does the plateau happen?

Metabolic adaptation

When you lose weight, your body requires fewer calories to function. A smaller body has less tissue to maintain, fewer cells to feed, and a lower resting metabolic rate (RMR). Research by Dr. Kevin Hall and colleagues, published in the journal Obesity (2012), showed that the body's energy expenditure drops significantly during weight loss — and this drop is often larger than predicted by body size alone. The body also increases hunger hormones such as ghrelin and reduces satiety hormones, trying to restore the lost weight.

On GLP-1 medications, this hunger signal is partially suppressed — but the metabolic slowdown still occurs. This means that the calorie deficit that worked at the start of treatment eventually closes as your metabolism adapts.

What do the clinical trials show?

The major GLP-1 trials confirm that plateaus are the norm, not the exception:

These trials involved close clinical supervision, so real-world patients may hit a plateau earlier — often around months 6–12 on semaglutide.

Other common contributing factors

Beyond pure metabolic adaptation, several other factors contribute to a plateau:

What can you do to break through a plateau?

1. Check that you are on the right dose

If you are mid-titration, speak to your doctor about whether it is safe to move to the next dose level. Both semaglutide and tirzepatide show greater weight loss at higher doses, and the maximum dose may not have been reached yet.

2. Add or increase resistance training

Strength training is one of the most effective tools against plateau. It builds or preserves muscle mass, raising your resting metabolic rate. Even two to three sessions per week of moderate strength work — squats, lunges, push-ups, dumbbell exercises — make a measurable difference over weeks. Resistance training also improves insulin sensitivity, which supports further weight loss.

3. Prioritise protein intake

Protein has the highest thermic effect of all macronutrients — your body burns more calories digesting it than it does digesting fat or carbohydrates. More importantly, adequate protein (1.2–1.6 grams per kilogram of body weight per day) protects muscle mass during weight loss. On GLP-1 medication, reduced appetite can lead to protein under-consumption; actively planning protein-rich meals helps counteract this.

4. Audit your calorie-dense intake honestly

Keep a food diary for a week without changing anything — just recording. Many people discover that calorie-dense liquids (fruit juice, alcohol, smoothies, specialty coffees) or small habitual snacks have crept back in. A single daily latte with syrup can add 150–250 calories; three small biscuits can add another 150. These additions are easy to overlook but can completely close a calorie deficit.

5. Protect your sleep

Seven to nine hours of quality sleep per night is not a luxury during weight loss — it is a physiological requirement. Sleep deprivation directly raises ghrelin and lowers leptin, making you hungrier the next day even when taking GLP-1 medication. Consistently poor sleep can stall weight loss entirely. Establish a regular sleep schedule, limit screens before bed, and keep the bedroom cool and dark.

6. Manage stress actively

Chronic psychological stress drives cortisol production. Elevated cortisol increases appetite — particularly for calorie-dense foods — and promotes visceral fat storage. If life has been particularly stressful during your plateau period, this is worth addressing: regular moderate exercise, mindfulness practices, and social support all help reduce cortisol levels.

7. Talk to your doctor

If you have applied the above steps for two to three months and the plateau persists, discuss with your prescribing doctor. Options to consider include dose adjustment, a temporary medication switch, or adding complementary approaches under medical supervision. A plateau that does not respond to lifestyle modifications may occasionally reflect an underlying hormonal issue (such as hypothyroidism) that is worth investigating.

A plateau is not failure

It can be deeply discouraging to watch the scale stop moving after months of progress. But it is important to remember what a plateau actually means: your body has already achieved a significant change in weight and metabolic health. You are maintaining a lower weight in a body that has never been at this point before — and that maintenance itself represents genuine success.

Clinical data shows that even when weight loss stalls, many metabolic benefits of GLP-1 treatment continue — improved blood sugar control, reduced blood pressure, better cardiovascular risk markers, and improved liver health. The scale is only one measure of progress.

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your doctor before making changes to your medication, diet or exercise routine during GLP-1 treatment.

Sources